Heat Biologics Priced, Nasdaq: HTBX
Developing cellular therapeutic vaccines for cancer therapy.
Industry: Health Care
First Day Return: -4.3%
HTBX
Developing cellular therapeutic vaccines for cancer therapy.
| IPO Data | |
|---|---|
| IPO Date | 07/23/2013 |
| Offer Price | IPO Intelligence Only |
| Price Range | IPO Intelligence Only |
| Offer Shares (mm) | IPO Intelligence Only |
| Deal Size ($mm) | $25 |
| Lock-Up Date | IPO Intelligence Only |
| Street Research | IPO Intelligence Only |
| Underwriters |
|---|
| IPO Intelligence Only |
| Company Data | |
|---|---|
| Headquarters | Chapel Hill, NC, United States |
| Founded | 2008 |
| Employees at IPO | 12 |
| Website www.heatbio.com | |
IPO News for Heat Biologics
Heat Biologics (HTBX) Performance
